Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Predictors of cardiovascular health in teenagers (aged 13-14 years): a cross-sectional study linked with routine data.

James M, Christian D, Scott S, Todd C, Stratton G, Demmler J, McCoubrey S, Halcox JP, Audrey S, Ellins EA, Brophy S.

Open Heart. 2019 Oct 28;6(2):e001147. doi: 10.1136/openhrt-2019-001147. eCollection 2019.

2.

Early Discontinuation of P2Y12 Antagonists and Adverse Clinical Events Post-Percutaneous Coronary Intervention: A Hospital and Primary Care Linked Cohort.

Harris DE, Lacey A, Akbari A, Obaid DR, Smith DA, Jenkins GH, Barry JP, Gravenor MB, Halcox JP.

J Am Heart Assoc. 2019 Nov 5;8(21):e012812. doi: 10.1161/JAHA.119.012812. Epub 2019 Oct 29.

3.

Associations of depression-anxiety and dyslipidaemia with subclinical carotid arterial disease: Findings from the Whitehall II Study.

Ellins EA, Shipley MJ, Rees DA, Kemp A, Deanfield JE, Brunner EJ, Halcox JP.

Eur J Prev Cardiol. 2019 Sep 17:2047487319876230. doi: 10.1177/2047487319876230. [Epub ahead of print]

PMID:
31529992
4.

Carotid artery wave intensity in mid- to late-life predicts cognitive decline: the Whitehall II study.

Chiesa ST, Masi S, Shipley MJ, Ellins EA, Fraser AG, Hughes AD, Patel RS, Khir AW, Halcox JP, Singh-Manoux A, Kivimaki M, Celermajer DS, Deanfield JE.

Eur Heart J. 2019 Jul 21;40(28):2300-2309. doi: 10.1093/eurheartj/ehz189.

5.

Chronic kidney disease, cardiovascular risk markers and total mortality in older men: cystatin C versus creatinine.

Zonoozi S, Ramsay SE, Papacosta O, Lennon LT, Ellins EA, Halcox JPJ, Whincup P, Wannamethee SG.

J Epidemiol Community Health. 2019 Jul;73(7):645-651. doi: 10.1136/jech-2018-211719. Epub 2019 Mar 19.

PMID:
30890591
6.

Risk classification in primary prevention of CVD according to QRISK2 and JBS3 'heart age', and prevalence of elevated high-sensitivity C reactive protein in the UK cohort of the EURIKA study.

Johns I, Moschonas KE, Medina J, Ossei-Gerning N, Kassianos G, Halcox JP.

Open Heart. 2018 Nov 17;5(2):e000849. doi: 10.1136/openhrt-2018-000849. eCollection 2018.

7.

A genetic programming approach to development of clinical prediction models: A case study in symptomatic cardiovascular disease.

Bannister CA, Halcox JP, Currie CJ, Preece A, Spasić I.

PLoS One. 2018 Sep 4;13(9):e0202685. doi: 10.1371/journal.pone.0202685. eCollection 2018.

8.

Response by Halcox and Wareham to Letter Regarding Article, "Assessment of Remote Heart Rhythm Sampling Using the AliveCor Heart Monitor to Screen for Atrial Fibrillation: The REHEARSE-AF Study".

Halcox JPJ, Wareham K.

Circulation. 2018 May 15;137(20):2193-2194. doi: 10.1161/CIRCULATIONAHA.118.033773. No abstract available.

PMID:
29760234
9.

Ready-to-use food supplement, with or without arginine and citrulline, with daily chloroquine in Tanzanian children with sickle-cell disease: a double-blind, random order crossover trial.

Cox SE, Ellins EA, Marealle AI, Newton CR, Soka D, Sasi P, Luca Di Tanna G, Johnson W, Makani J, Prentice AM, Halcox JP, Kirkham FJ.

Lancet Haematol. 2018 Apr;5(4):e147-e160. doi: 10.1016/S2352-3026(18)30020-6. Epub 2018 Mar 13.

10.

Arterial pathophysiology and comparison of two devices for pulse wave velocity assessment in elderly men: the British regional heart study.

Ellins EA, Smith KE, Lennon LT, Papacosta O, Wannamethee SG, Whincup PH, Halcox JP.

Open Heart. 2017 Dec 17;4(2):e000645. doi: 10.1136/openhrt-2017-000645. eCollection 2017.

11.

Serum uric acid levels are associated with cardiovascular risk score: A post hoc analysis of the EURIKA study.

Borghi C, Rodriguez-Artalejo F, De Backer G, Dallongeville J, Medina J, Nuevo J, Guallar E, Perk J, Banegas JR, Tubach F, Roy C, Halcox JP.

Int J Cardiol. 2018 Feb 15;253:167-173. doi: 10.1016/j.ijcard.2017.10.045.

PMID:
29306459
12.

Evolving landscape of stroke prevention in atrial fibrillation within the UK between 2012 and 2016: a cross-sectional analysis study using CPRD.

Lacoin L, Lumley M, Ridha E, Pereira M, McDonald L, Ramagopalan S, Lefèvre C, Evans D, Halcox JP.

BMJ Open. 2017 Sep 25;7(9):e015363. doi: 10.1136/bmjopen-2016-015363.

13.

Assessment of Remote Heart Rhythm Sampling Using the AliveCor Heart Monitor to Screen for Atrial Fibrillation: The REHEARSE-AF Study.

Halcox JPJ, Wareham K, Cardew A, Gilmore M, Barry JP, Phillips C, Gravenor MB.

Circulation. 2017 Nov 7;136(19):1784-1794. doi: 10.1161/CIRCULATIONAHA.117.030583. Epub 2017 Aug 28.

PMID:
28851729
14.

Circulating soluble receptor for advanced glycation end product: Cross-sectional associations with cardiac markers and subclinical vascular disease in older men with and without diabetes.

Wannamethee SG, Welsh P, Papacosta O, Ellins EA, Halcox JPJ, Whincup PH, Sattar N.

Atherosclerosis. 2017 Sep;264:36-43. doi: 10.1016/j.atherosclerosis.2017.07.008. Epub 2017 Jul 12.

15.

Self-reported sleep duration and napping, cardiac risk factors and markers of subclinical vascular disease: cross-sectional study in older men.

Zonoozi S, Ramsay SE, Papacosta O, Lennon L, Ellins EA, Halcox JPJ, Whincup PH, Goya Wannamethee S.

BMJ Open. 2017 Jul 2;7(6):e016396. doi: 10.1136/bmjopen-2017-016396.

16.

Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study.

Halcox JP, Banegas JR, Roy C, Dallongeville J, De Backer G, Guallar E, Perk J, Hajage D, Henriksson KM, Borghi C.

BMC Cardiovasc Disord. 2017 Jun 17;17(1):160. doi: 10.1186/s12872-017-0591-5.

17.

Risk of cardiovascular events, arrhythmia and all-cause mortality associated with clarithromycin versus alternative antibiotics prescribed for respiratory tract infections: a retrospective cohort study.

Berni E, de Voogd H, Halcox JP, Butler CC, Bannister CA, Jenkins-Jones S, Jones B, Ouwens M, Currie CJ.

BMJ Open. 2017 Jan 23;7(1):e013398. doi: 10.1136/bmjopen-2016-013398.

18.

Increased fibrinogen responses to psychophysiological stress predict future endothelial dysfunction implications for cardiovascular disease?

Ellins EA, Rees DA, Deanfield JE, Steptoe A, Halcox JP.

Brain Behav Immun. 2017 Feb;60:233-239. doi: 10.1016/j.bbi.2016.10.017. Epub 2016 Oct 18.

PMID:
27769916
19.

The association between blood pressure and lipid levels in Europe: European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice.

Borghi C, Rodriguez-Artalejo F, De Backer G, Dallongeville J, Medina J, Guallar E, Perk J, Banegas JR, Tubach F, Roy C, Halcox JP.

J Hypertens. 2016 Nov;34(11):2155-63. doi: 10.1097/HJH.0000000000001078.

PMID:
27512970
20.

Objectively measured physical activity, sedentary time and subclinical vascular disease: Cross-sectional study in older British men.

Parsons TJ, Sartini C, Ellins EA, Halcox JPJ, Smith KE, Ash S, Lennon LT, Wannamethee SG, Lee IM, Whincup PH, Jefferis BJ.

Prev Med. 2016 Aug;89:194-199. doi: 10.1016/j.ypmed.2016.05.031. Epub 2016 May 31.

21.

Lack of control of hypertension in primary cardiovascular disease prevention in Europe: Results from the EURIKA study.

Borghi C, Tubach F, De Backer G, Dallongeville J, Guallar E, Medina J, Perk J, Roy C, Banegas JR, Rodriguez-Artalejo F, Halcox JP.

Int J Cardiol. 2016 Sep 1;218:83-88. doi: 10.1016/j.ijcard.2016.05.044. Epub 2016 May 13.

PMID:
27232917
22.

Objectively measured physical activity and sedentary behaviour and ankle brachial index: Cross-sectional and longitudinal associations in older men.

Parsons TJ, Sartini C, Ellins EA, Halcox JP, Smith KE, Ash S, Lennon LT, Wannamethee SG, Lee IM, Whincup PH, Jefferis BJ.

Atherosclerosis. 2016 Apr;247:28-34. doi: 10.1016/j.atherosclerosis.2016.01.038. Epub 2016 Jan 25.

23.

HbA1c measurement and relationship to incident stroke.

Robson R, Lacey AS, Luzio SD, Van Woerden H, Heaven ML, Wani M, Halcox JP, Castilla-Guerra L, Dawson J, Hewitt J.

Diabet Med. 2016 Apr;33(4):459-62. doi: 10.1111/dme.13057. Epub 2016 Jan 18.

24.

Validation of a new method for non-invasive assessment of vasomotor function.

Ellins EA, New KJ, Datta DB, Watkins S, Haralambos K, Rees A, Aled Rees D, Halcox JP.

Eur J Prev Cardiol. 2016 Apr;23(6):577-83. doi: 10.1177/2047487315597210. Epub 2015 Jul 24.

PMID:
26209709
25.

Low rates of both lipid-lowering therapy use and achievement of low-density lipoprotein cholesterol targets in individuals at high-risk for cardiovascular disease across Europe.

Halcox JP, Tubach F, Lopez-Garcia E, De Backer G, Borghi C, Dallongeville J, Guallar E, Medina J, Perk J, Sazova O, Sweet S, Roy C, Banegas JR, Rodriguez-Artalejo F.

PLoS One. 2015 Feb 18;10(2):e0115270. doi: 10.1371/journal.pone.0115270. eCollection 2015.

26.

Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls.

Bannister CA, Holden SE, Jenkins-Jones S, Morgan CL, Halcox JP, Schernthaner G, Mukherjee J, Currie CJ.

Diabetes Obes Metab. 2014 Nov;16(11):1165-73. doi: 10.1111/dom.12354. Epub 2014 Jul 31.

PMID:
25041462
27.

Central arterial stiffness and diastolic dysfunction are associated with insulin resistance and abdominal obesity in young women but polycystic ovary syndrome does not confer additional risk.

Rees E, Coulson R, Dunstan F, Evans WD, Blundell HL, Luzio SD, Dunseath G, Halcox JP, Fraser AG, Rees DA.

Hum Reprod. 2014 Sep;29(9):2041-9. doi: 10.1093/humrep/deu180. Epub 2014 Jul 17.

PMID:
25035436
28.

Higher systolic blood pressure with normal vascular function measurements in preterm-born children.

Edwards MO, Watkins WJ, Kotecha SJ, Halcox JP, Dunstan FD, Henderson AJ, Kotecha S.

Acta Paediatr. 2014 Sep;103(9):904-12. doi: 10.1111/apa.12699. Epub 2014 Jun 19. Review.

PMID:
24861771
29.

Lipid-lowering therapy and mortality post-MI: is it just about the LDL?

Halcox JP, Currie CJ.

Heart. 2014 Jun;100(11):825-6. doi: 10.1136/heartjnl-2014-305556. Epub 2014 Mar 17. No abstract available.

PMID:
24637517
30.

C-reactive protein levels in patients at cardiovascular risk: EURIKA study.

Halcox JP, Roy C, Tubach F, Banegas JR, Dallongeville J, De Backer G, Guallar E, Sazova O, Medina J, Perk J, Steg PG, Rodríguez-Artalejo F, Borghi C.

BMC Cardiovasc Disord. 2014 Feb 24;14:25. doi: 10.1186/1471-2261-14-25.

31.

Chronic disease influences over 40 major life-changing decisions (MLCDs): a qualitative study in dermatology and general medicine.

Bhatti ZU, Finlay AY, Bolton CE, George L, Halcox JP, Jones SM, Ketchell RI, Moore RH, Salek MS.

J Eur Acad Dermatol Venereol. 2014 Oct;28(10):1344-55. doi: 10.1111/jdv.12289. Epub 2013 Oct 18.

PMID:
24134436
32.

Reclassification of European patients' cardiovascular risk using the updated Systematic Coronary Risk Evaluation algorithm.

Halcox JP, Tubach F, Sazova O, Sweet S, Medina J; EURIKA steering committee.

Eur J Prev Cardiol. 2015 Feb;22(2):200-2. doi: 10.1177/2047487313507680. Epub 2013 Oct 3.

PMID:
24092875
33.

The development and validation of the major life changing decision profile (MLCDP).

Bhatti ZU, Salek SS, Bolton CE, George L, Halcox JP, Jones SM, Ketchell IR, Moore RH, Sabit R, Piguet V, Finlay AY.

Health Qual Life Outcomes. 2013 May 8;11:78. doi: 10.1186/1477-7525-11-78.

34.

Low-dose sodium nitrite attenuates myocardial ischemia and vascular ischemia-reperfusion injury in human models.

Ingram TE, Fraser AG, Bleasdale RA, Ellins EA, Margulescu AD, Halcox JP, James PE.

J Am Coll Cardiol. 2013 Jun 25;61(25):2534-41. doi: 10.1016/j.jacc.2013.03.050. Epub 2013 Apr 23.

35.

Omega-3 Fatty acids and mortality outcome in patients with and without type 2 diabetes after myocardial infarction: a retrospective, matched-cohort study.

Poole CD, Halcox JP, Jenkins-Jones S, Carr ES, Schifflers MG, Ray KK, Currie CJ.

Clin Ther. 2013 Jan;35(1):40-51. doi: 10.1016/j.clinthera.2012.11.008. Epub 2012 Dec 13.

36.

Levels of circulating endothelial cells and colony-forming units are influenced by age and dyslipidemia.

Fabbri-Arrigoni FI, Clarke L, Wang G, Charakida M, Ellins E, Halliday N, Brogan PA, Deanfield JE, Halcox JP, Klein N.

Pediatr Res. 2012 Sep;72(3):299-304. doi: 10.1038/pr.2012.76. Epub 2012 Jun 12.

37.

Achievement of lipoprotein goals among patients with metabolic syndrome at high cardiovascular risk across Europe. The EURIKA study.

Banegas JR, López-García E, Dallongeville J, Guallar E, Halcox JP, Borghi C, Massó-González EL, Sazova O, Perk J, Steg PG, De Backer G, Rodríguez-Artalejo F.

Int J Cardiol. 2013 Jun 5;166(1):210-4. doi: 10.1016/j.ijcard.2011.10.094. Epub 2011 Nov 5.

PMID:
22056474
38.

Excess risk attributable to traditional cardiovascular risk factors in clinical practice settings across Europe - The EURIKA Study.

Guallar E, Banegas JR, Blasco-Colmenares E, Jiménez FJ, Dallongeville J, Halcox JP, Borghi C, Massó-González EL, Tafalla M, Perk J, De Backer G, Steg PG, Rodríguez-Artalejo F.

BMC Public Health. 2011 Sep 18;11:704. doi: 10.1186/1471-2458-11-704.

39.

The arterial pulse: vascular biology, vascular function testing, and therapies.

Zafari AM, Quyyumi AA, Halcox JP, Rajagopalan S.

Cardiol Res Pract. 2011;2011:151428. doi: 10.4061/2011/151428. Epub 2011 Sep 8. No abstract available.

40.

Where are we heading with noninvasive clinical vascular physiology? Why and how should we assess endothelial function?

Ellins EA, Halcox JP.

Cardiol Res Pract. 2011;2011:870132. doi: 10.4061/2011/870132. Epub 2011 Aug 16.

41.

Direct vasoactive properties of thienopyridine-derived nitrosothiols.

Bundhoo SS, Anderson RA, Sagan E, Dada J, Harris R, Halcox JP, Lang D, James PE.

J Cardiovasc Pharmacol. 2011 Nov;58(5):550-8. doi: 10.1097/FJC.0b013e31822f578c.

PMID:
21822146
42.
43.

Survey of physicians' practices in the control of cardiovascular risk factors: the EURIKA study.

Dallongeville J, Banegas JR, Tubach F, Guallar E, Borghi C, De Backer G, Halcox JP, Massó-González EL, Perk J, Sazova O, Steg PG, Artalejo FR; EURIKA Investigators.

Eur J Prev Cardiol. 2012 Jun;19(3):541-50. doi: 10.1177/1741826711407705. Epub 2011 Apr 18.

PMID:
21502280
44.

Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study.

Banegas JR, López-García E, Dallongeville J, Guallar E, Halcox JP, Borghi C, Massó-González EL, Jiménez FJ, Perk J, Steg PG, De Backer G, Rodríguez-Artalejo F.

Eur Heart J. 2011 Sep;32(17):2143-52. doi: 10.1093/eurheartj/ehr080. Epub 2011 Apr 6.

45.

Rationale and methods of the European Study on Cardiovascular Risk Prevention and Management in Daily Practice (EURIKA).

Rodríguez-Artalejo F, Guallar E, Borghi C, Dallongeville J, De Backer G, Halcox JP, Hernández-Vecino R, Jiménez FJ, Massó-González EL, Perk J, Steg PG, Banegas JR; EURIKA Investigators.

BMC Public Health. 2010 Jun 30;10:382. doi: 10.1186/1471-2458-10-382.

46.

Determinants of vascular phenotype in a large childhood population: the Avon Longitudinal Study of Parents and Children (ALSPAC).

Donald AE, Charakida M, Falaschetti E, Lawlor DA, Halcox JP, Golding J, Hingorani AD, Smith GD, Deanfield JE.

Eur Heart J. 2010 Jun;31(12):1502-10. doi: 10.1093/eurheartj/ehq062. Epub 2010 Apr 25.

47.

Niacin compared with ezetimibe.

Lindsay AC, Halcox JP.

N Engl J Med. 2010 Mar 18;362(11):1046; author reply 1048. doi: 10.1056/NEJMc0912942. No abstract available.

PMID:
20237352
48.

Increased arterial stiffness in HIV-infected children: risk factors and antiretroviral therapy.

Charakida M, Loukogeorgakis SP, Okorie MI, Masi S, Halcox JP, Deanfield JE, Klein NJ.

Antivir Ther. 2009;14(8):1075-9. doi: 10.3851/IMP1437.

PMID:
20032537
49.

Endothelial response to childhood infection: the role of mannose-binding lectin (MBL).

Charakida M, Donald AE, Leary S, Halcox JP, Turner MW, Johnson M, Loukogeorgakis SP, Okorie MI, Davey Smith G, Deanfield JE, Klein NJ.

Atherosclerosis. 2010 Jan;208(1):217-21. doi: 10.1016/j.atherosclerosis.2009.07.055. Epub 2009 Aug 8.

PMID:
19709662
50.

Vascular impact of progenitor cell mobilisation for cardiac repair post-myocardial infarction.

Freeman PM, Halcox JP.

Heart. 2009 Aug;95(16):1301-2. doi: 10.1136/hrt.2008.163915. Epub 2009 May 20. No abstract available.

PMID:
19460771

Supplemental Content

Loading ...
Support Center